Related Experiment Video

Updated: Aug 16, 2026

Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine
12:37

Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine

Published on: February 9, 2016

[Changes of activity of the endothelial system in experimental heart failure]

M I Popovich, V A Kobets, M P Todirash

    Kardiologiia
    |August 11, 2005
    PubMed

    Insights

    Endothelin receptor antagonists show promise for heart failure treatment. Selective ET(A) antagonists are effective early, while nonselective ET(AB) antagonists offer greater benefits in later stages of heart failure.

    Area of Science:

    • Cardiovascular Research
    • Pharmacology

    Background:

    • Endothelins play a role in heart failure pathogenesis.
    • Endothelin receptor antagonist (ERA) therapy requires further elucidation for heart failure.
    • Experimental heart failure involves altered endothelin receptor signaling.

    Purpose of the Study:

    • To investigate the therapeutic potential of endothelin receptor antagonists in experimental heart failure.
    • To understand the role of ET(A) and ET(B) receptors in heart failure-induced vascular dysfunction.

    Main Methods:

    • Induction of experimental heart failure via prolonged norepinephrine infusion.
    • Assessment of endothelin-induced coronary vasoconstriction and vasodilation.
    • Evaluation of selective ET(A) and nonselective ET(AB) antagonist efficacy at different stages of heart failure.

    Main Results:

    • Heart failure diminished ET(A) receptor-mediated vasoconstriction and inverted ET(A) receptor-mediated vasodilation.
    • The inverted vasodilation was linked to smooth muscle ET(B)-receptors, indicating endothelial dysfunction.
    • Selective ET(A) antagonists were effective in early-stage heart failure.
    • Nonselective ET(AB) antagonists demonstrated more pronounced effects in later stages of heart failure.

    Conclusions:

    • Endothelin receptor antagonism is a viable therapeutic strategy for heart failure.
    • Therapeutic approach should be tailored to the stage of heart failure.
    • Nonselective ET(AB) antagonists may be more beneficial in advanced heart failure stages.

    Related Concept Videos

    Heart Failure II: Pathophysiology01:29

    Heart Failure II: Pathophysiology

    Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
    Pathophysiology of Heart Failure01:17

    Pathophysiology of Heart Failure

    Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Heart Failure I: Introduction01:27

    Heart Failure I: Introduction

    Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    Heart Failure VII: Nursing Interventions01:30

    Heart Failure VII: Nursing Interventions

    The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...